Patents Examined by Richard Schnizer
  • Patent number: 11000600
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: May 11, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Patent number: 10980779
    Abstract: The present invention relates to methods and pharmaceutical compositions useful for the treatment of hyperglycemia. Thorough multiple analyses, inventors demonstrated that Gfi1 is expressed in pancreatic acinar cells, starting from the first stages of pancreatic embryonic development. Furthermore, they observed that Gfi1 mRNA levels remain steady throughout embryonic development, while they significantly increase during the first days of life. They challenged conditional mutant mice with high fat diet for 5 months and monitored their weight and glycemia weekly. All the animals displayed a rapid increase in body mass as expected. While control mice rapidly developed a massive hyperglycemia, mutant mice remained normoglycemic throughout the entire experiment. A similar protection from induced diabetes was observed upon treatment with a high dose of Streptozotocin.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: April 20, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Patrick Collombat, Tiziana Napolitano, Fabio Avolio
  • Patent number: 10976313
    Abstract: Multiplex immunoassays utilize the differential affinities among the conjugation pairs between the capture ligands and target analytes are proposed. Window magnetic-assisted rapid aptamer selection (window-MARAS) methods for selecting aptamers with desirable affinity toward the target analytes and methods for generating reagents for multiplex immunoassays or multiplex detection in one assay by utilizing the selected aptamers as capture ligands in reagents are described and used to demonstrate the feasibility of multiplex immunoassays based on the differential affinity of conjugation pairs between the capture ligands and target analytes.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: April 13, 2021
    Inventors: Chin-Yih Hong, Herng-Er Horng
  • Patent number: 10968451
    Abstract: Nucleic acid molecules such as shRNA clusters and artificial miRNA clusters are disclosed, Also disclosed are methods of use, compositions, cells, viral particles, and kits relating to the nucleic acid molecules disclosed herein. The disclosure provides, at least in part nucleic acid molecules such as shRNA clusters encoding shRNA-like molecules and artificial miRNA clusters encoding modified pri-miRNA-like molecules. The shRNA clusters and artificial miRNA clusters disclosed herein can be used, for example, to produce artificial RNA molecules, e.g., RNAi molecules. Cells, viral particles, compositions (e.g., pharmaceutical compositions), kits, and methods relating to the nucleic acid molecules, e.g., shRNA clusters and artificial miRNA clusters, are also disclosed. The nucleic acid molecules (e.g., shRNA clusters and artificial miRNA clusters), artificial RNA molecules (e.g., RNAi molecules), cells, viral particles, compositions (e.g.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 6, 2021
    Assignee: Texas Tech University System
    Inventors: Haoquan Wu, Jang-gi Choi
  • Patent number: 10952972
    Abstract: The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 23, 2021
    Assignee: Pfizer Inc.
    Inventors: Allen Thomas Horhota, Young-Ho Song, Ujjwal Chaitanya Joshi, Nicholas Jon Boylan, Matthew John Simmons
  • Patent number: 10947542
    Abstract: The present invention relates to nucleic acid molecules that simultaneously inhibit the expression of AR gene and mTOR gene, wherein the double-stranded siRNA and shRNA of the present invention were designed to simultaneously inhibit the expression of the AR gene and the mTOR gene which are associated with cancer. The double-stranded siRNA and shRNA of the present invention promote cancer cell death and synergistically enhance cancer cell death in combination with an anticancer agent, so that various types of cancer may be effectively prevented and treated.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: March 16, 2021
    Assignee: CURIGIN CO., LTD.
    Inventors: Jin-Woo Choi, Jung-Ki Yoo
  • Patent number: 10947531
    Abstract: The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: March 16, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Sherry Lynn La Porte, Stephen James Moore, James William West
  • Patent number: 10947543
    Abstract: The present invention provides a small hairpin nucleic acid molecule that is capable of stimulating interferon production. The nucleic acid molecule of the present invention has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5? triphosphate or a 5? diphosphate.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 16, 2021
    Assignee: Yale University
    Inventors: Anna Marie Pyle, Andrew Kohlway, Dahai Luo, David Rawling, Akiko Iwasaki
  • Patent number: 10934547
    Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 2, 2021
    Assignee: Northwestern University
    Inventors: Marcus E. Peter, Andrea E. Murmann
  • Patent number: 10920226
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for LDHA.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 16, 2021
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 10913946
    Abstract: The current invention provides an improved oligonucleotide and its use for treating, ameliorating, preventing and/or delaying DMD or BMD.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 9, 2021
    Assignee: BioMarin Technologies B.V.
    Inventors: Peter Christian de Visser, Judith Christina Theodora van Deutekom
  • Patent number: 10913767
    Abstract: This invention relates to an oligonucleotide comprising one or more abasic nucleoside monomers of formula V: These monomers are useful for modifying of oligonucleotides at one or more positions. This invention also relates to a method of inhibiting the expression of a target gene in a cell. The method comprises contacting the cell with an oligonucleotide having one or more of the above formula (V).
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: February 9, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jeremy Lackey, Narayanannair K. Jayaprakash
  • Patent number: 10905782
    Abstract: Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: February 2, 2021
    Assignee: Sarepta Therapeutics, inc.
    Inventors: Patrick L. Iversen, Hong M. Moulton, Michelle H. Nelson, David A. Stein, Andrew D. Kroeker
  • Patent number: 10888578
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Patent number: 10883118
    Abstract: New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 5, 2021
    Assignee: Molecular Transfer Inc.
    Inventors: Joel Jessee, Gulilat Gebeyehu
  • Patent number: 10875884
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 29, 2020
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Patent number: 10876116
    Abstract: Antisense compounds for suppressing expression of ARTD3a are disclosed, as well as pharmaceutical compositions containing same and methods of producing and using same. The antisense compounds can be used to treat inflammatory disorders and conditions related to interferon-alpha production.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: December 29, 2020
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Carol F. Webb, Julie Ward, Michelle Ratliff
  • Patent number: 10837015
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 17, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Patent number: 10829511
    Abstract: This invention covers oligonucleotide analogs that fold in part by having a segment of consecutive pyrimidine analogs form pyrimidine analog:pyrimidine analog pairs with another a segment of consecutive pyrimidine analogs segment, and where the segments pair by pyrimidine analog:pyrimidine analog “skinny” pairing. This pairing retains hydrogen bonding complementarity seen in standard DNA.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: November 10, 2020
    Inventors: Steven A Benner, Shuichi Hoshika
  • Patent number: 10829812
    Abstract: This invention relates to processes that amplify oligonucleotide analogs that incorporate non-standard nucleobase analogs from an artificially expanded genetic information system. These pair in DNA duplexes via patterns of hydrogen bonds that differ from patterns that join the thymine-adenine and guanine-cytosine nucleobase pairs.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: November 10, 2020
    Inventors: Steven A Benner, Roberto Laos, Nicole A Leal, Zunyi Yang, Myong Jung Kim